«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 17

Page:

3392-3397

Research Field:

Publishing date:

Info

Title:

Diagnosis and treatment status and progress of EGFR exon 20 insertion mutation non-small cell lung cancer

Author(s):

SHENG Shu¹; 2; MAO Yunye¹; ZHAI Jinzhao³; LU Di¹; GE Xiangwei¹; JIA Yangyang¹; QIN Boyu³; LYU Donglai²; WANG Jinliang¹; 3

1.Graduate School,General Hospital of PLA/Chinese PLA Medical School,Beijing 100853,China£»2.Department of Oncology,the 901th Hospital of the Chinese People's Liberation Army Joint Security Force,Anhui Hefei 230031,China£»3.Department of Oncology,the Fifth Medical Center,General Hospital of PLA,Beijing 100071,China.

Keywords:

non-small cell lung cancer; EGFR exon 20 insertion mutation; progress in targeted therapy

PACS:

R734.2

DOI:

10.3969/j.issn.1672-4992.2024.17.037

Abstract:

Epidermal growth factor receptor (EGFR) gene mutations are highly prevalent in non-small cell lung cancer (NSCLC) and exhibit significant structural and functional diversity due to variations in mutation sites.Presently,there is a range of targeted drugs available for treating EGFR mutations.Of these mutations,EGFR exon 20 insertion mutations(ex20ins) constitute approximately 4%~12% and rank third in frequency after EGFR exon 19 deletion mutations and EGFR exon 21 L858R mutations.The heterogeneity of EGFR ex20ins mutations is evident as they occur at different insertion sites,resulting in varying sensitivities to existing targeted drugs for EGFR.Unfortunately,most of those patients with EGFR ex20ins mutations exhibit limited response to these targeted drugs,and as a result,chemotherapy remains the primary treatment option.Nonetheless,intensive research efforts have led to the development of various drugs that are currently undergoing clinical trials specifically targeting this mutation.This article aims to provide a comprehensive review of the structure and function of EGFR ex20ins mutations,and treatment progress,with the objective of offering novel perspectives for clinical management.

References:

£Û1£ÝSIEGEL RL,GIAQUINTO AN,JEMAL A.Cancer statistics,2024£ÛJ£Ý.CA Cancer J Clin,2024£¬74(1):12-49.
£Û2£ÝGOU LY,WU YL.Prevalence of driver mutations in non-small-cell lung cancers in the people's republic of China£ÛJ£Ý.Lung Cancer(Auckl),2014,5:1-9.
£Û3£ÝBURNETT H,EMICH H,CARROLL C,et al.Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer:A systematic literature review£ÛJ£Ý.PLoS One,2021,16(3):e0247620.
£Û4£ÝDA CUNHA SANTOS G,SHEPHERD FA,TSAO MS.EGFR mutations and lung cancer£ÛJ£Ý.Annu Rev Pathol,2011,6:49-69.
£Û5£ÝYASUDA H,KOBAYASHI S,COSTA DB.EGFR exon 20 insertion mutations in non-small-cell lung cancer:preclinical data and clinical implications£ÛJ£Ý.Lancet Oncol,2012,13(1):e23-31.
£Û6£ÝREMON J,HENDRIKS LEL,CARDONA AF,et al.EGFR exon 20 insertions in advanced non-small cell lung cancer:A new history begins£ÛJ£Ý.Cancer Treat Rev,2020,90:102105.
£Û7£ÝÖйúÁÙ´²Ö×Áöѧ»á·ÇСϸ°û·Î°©×¨¼ÒίԱ»á.EGFR 20ÍâÏÔ×Ó²åÈëÍ»±ä·ÇСϸ°û·Î°©¹æ·¶»¯ÕïÁÆÖйúר¼Ò¹²Ê¶£¨2023°æ£©£ÛJ£Ý.Öйú·Î°©ÔÓÖ¾,2023,26(05):325-337. Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee.Chinese expert consensus on non-small cell lung cancer with EGFR exon 20 insertion mutations(2023 edition)£ÛJ£Ý.Chinese Lung Cancer Journa£¬2023£¬26(05):325-337.
£Û8£ÝÑîÑ©,ÕÔ¾ü.EGFRÍâÏÔ×Ó20²åÈëÍ»±äÑôÐÔNSCLCÖÎÁƵÄÁÙ´²Ñо¿½øÕ¹£ÛJ£Ý.Öйú·Î°©ÔÓÖ¾,2022,25(05):337-350. YANG X,ZHAO J.Advances in treatment of non-small cell lung cancer harboring EGFR exon 20 insertion mutations£ÛJ£Ý.Chinese Lung Cancer Journal£¬2022,25(05):337-350.
£Û9£ÝYANG G,LI J,XU H,et al.EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients:Molecular heterogeneity and treatment outcome from nationwide real-world study£ÛJ£Ý.Lung Cancer,2020,145:186-194.
£Û10£ÝYASUDA H,PARK E,YUN CH,et al.Structural,biochemical,and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer£ÛJ£Ý.Sci Transl Med,2013,5(216):216ra177.
£Û11£ÝSHAH MP,AREDO JV,PADDA SK,et al.EGFR exon 20 insertion NSCLC and response to platinum-based chemotherapy£ÛJ£Ý.Clin Lung Cancer,2022,23(2):e148-e153.
£Û12£ÝKWON CS,LIN HM,CROSSLAND V,et al.Non-small cell lung cancer with EGFR exon 20 insertion mutation:a systematic literature review and meta-analysis of patient outcomes£ÛJ£Ý.Curr Med Res Opin,2022,38(8):1341-1350.
£Û13£ÝÕżѻÛ, ¹ùÆäÉ­,Õųõ·å,µÈ. EGFR 20ÍâÏÔ×Ó²åÈëÍ»±äÍíÆÚNSCLC»¯ÁÆÁªºÏÃâÒßÖÎÁƶԱÈÁªºÏ±´·¥Öéµ¥¿¹ÁÙ´²·ÖÎö£ÛJ£Ý.ÖлªÖ×Áö·ÀÖÎÔÓÖ¾,2022,29(11):828-833. ZHANG JH,GUO QS,ZHANG CF,et al.Clinical analysis of chemotherapy combined with immunetheraphy versus with bevacizumab in treatment of advanced NSCLC with EGFR 20 exon insertion mutations£ÛJ£Ý.Chinese Journal of Cancer Prevention and Treatment£¬2022,29 (11):828-833.
£Û14£ÝZHI X,LUO J,LI W,et al.Case report:Osimertinib followed by osimertinib plus bevacizumab,personalized treatment strategy for a lung cancer patient with a novel EGFR exon 20 insertion D770_N771insGT and multiple brain metastases£ÛJ£Ý.Front Oncol,2021,11:733276.
£Û15£ÝGIRARD N,MINCHOM A,OU SI,et al.Comparative clinical outcomes between EGFR Ex20ins and wildtype NSCLC treated with immune checkpoint inhibitors£ÛJ£Ý.Clin Lung Cancer,2022,23(7):571-577.
£Û16£ÝZHANG M,HUANG Q,YU M,et al.Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations:a real-world analysis£ÛJ£Ý.Transl Lung Cancer Res,2023,12(4):797-807.
£Û17£ÝTRUMMER A,BETHGE A,DICKGREBER N,et al.NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy£ÛJ£Ý.Lung Cancer,2022,174:141-145.
£Û18£ÝYANG M,XU X,CAI J,et al.NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors£ÛJ£Ý.Int J Cancer,2016,139(1):171-176.
£Û19£ÝYASUDA H,ICHIHARA E,SAKAKIBARA-KONISHI J,et al.A phase ¢ñ/¢ò study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer£ÛJ£Ý.Lung Cancer,2021,162:140-146.
£Û20£ÝZWIERENGA F,VAN VEGGEL B,HENDRIKS LEL,et al.High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC:Results from the phase 2 multicenter POSITION20 trial£ÛJ£Ý.Lung Cancer,2022,170:133-140.
£Û21£ÝYANG GJ,LI J,XU HY,et al.Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations£ÛJ£Ý.Lung Cancer,2021,152:39-48.
£Û22£ÝHAN BH,ZHOU CH,ZHENG W,et al.A phase 1b study of furmonertinib,an oral,brain penetrant,selective EGFR inhibitor,in patients with advanced NSCLC with EGFR exon 20 insertions£ÛJ£Ý.Journal of Thoracic Oncology,2023,18(11):S49.
£Û23£ÝPARK K,HAURA EB,LEIGHL NB,et al.Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy:initial results from the chrysalis phase ¢ñ study£ÛJ£Ý.J Clin Oncol,2021,39(30):3391-3402.
£Û24£ÝWANG MZ,FAN Y,SUN ML,et al.Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6):single-arm,open-label,multicentre,phase 2 trial£ÛJ£Ý.Lancet Respir Med,2024,12(3):217-224.
£Û25£ÝYANG JCH,WANG M,CHIU CH,et al.1325P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations£ÛJ£Ý.Annals of Oncology,2023,34:S765.
£Û26£ÝGONZALVEZ F,VINCENT S,BAKER TE,et al.Mobocertinib (TAK-788):A targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer£ÛJ£Ý.Cancer Discov,2021,11(7):1672-1687.
£Û27£ÝJ¦BNNE PA,WANG BC,CHO BC,et al.507O EXCLAIM-2:Phase ¢ó trial of first-line(1L) mobocertinib versus platinum-based chemotherapy in patients(pts) with epidermal growth factor receptor(EGFR) exon 20 insertion(ex20ins)+locally advanced/metastatic NSCLC£ÛJ£Ý.Annals of Oncology,2023,34:S1663-S1664.
£Û28£Ý ELAMIN YY,ROBICHAUX JP,CARTER BW,et al.Poziotinib for EGFR exon 20-mutant NSCLC:Clinical efficacy,resistance mechanisms,and impact of insertion location on drug sensitivity£ÛJ£Ý.Cancer Cell,2022,40(7):754-767,e756.
£Û29£ÝZHOU C,TANG KJ,CHO BC,et al.Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions£ÛJ£Ý.N Engl J Med,2023,389(22):2039-2051.
£Û30£ÝVAN VEGGEL B,VAN DER WEKKEN AJ,PAATS MS,et al.A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer£ÛJ£Ý.Cancer,2024,130(5):683-691.
£Û31£ÝWANG Q,WANG W,PAN W,et al.Case report:Two patients with EGFR exon 20 insertion mutanted non-small cell lung cancer precision treatment using patient-derived xenografts in zebrafish embryos£ÛJ£Ý.Front Oncol,2022,12:884798.

Memo

Memo:

-

Common functions

Last Update: 2024-07-31